Daito's Facts and Figures
- Top
- Company Profile
- Company Profile
- Daito's Facts and Figures
Net Sales (Consolidated)
506億円
（2025年5月期 連結売上高）
ダイトグループの売上高は506億円
2010年の上場以来、実質14期連続増収（※）を続け、上場当初の2倍以上の売上高となっています。
- The "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29) will be adopted from the fiscal year ended May 31, 2022. A comparison with estimates based on the application of the standard for the prior years before the standard's adoption will be used to determine the amount of revenue recognized.
Percentages of Sales from the Active Pharmaceutical Ingredients (API) Business and the Formulation Product Business
API business : 45 %
Pharmaceutical product business : 54 %
原薬から製剤までの2つの領域を手掛けることにより、両部門の営業情報を共有化したり、自社で原薬から製剤までを一貫製造することにより高品質・低コストを実現するなど、2つの領域の相乗効果がダイトの強みの1つです。
Annual Number of Tablets Daito Produces
Approx.
3,000
hundred million (3.2 billion)
（2025年5月期実績値）
ダイトの錠剤の生産数は約30億錠。
これは、日本人一人当たり、およそ年間24錠となります。
くすりをお使いになる方なら、きっと一度はダイトの医薬品を服用されていることでしょう。
（錠剤以外にも、顆粒剤などの製造を行っております。）
Reduction in Japan’s National Medical Expenditure, Achieved through Daito’s Provision of Generic Drugs
425
hundred million yen (46.8 billion yen)
（2025年5月期 出荷数量ベース）
ダイトが主力としているジェネリック医薬品は、先発医薬品の特許が満了した後に発売されるため、開発費が安価で、その薬価も先発医薬品の4割～5割未満です。
ダイトのジェネリック医薬品が先発品に置き換わることによる医療費削減効果は、約425億円でした。
Number of Master Files (MFs) Registered
106
（2025年5月現在。子会社、グループ会社の登録件数を含む。）
The number of officially registered MFs of the company almost equals the number of API products the company manufactures. A total of 106 MFs are officially registered for Daito Group products, the largest number in Japan.
An MF is a kind of component part of an application for approval for a drug. The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices provides that the MF for an API shall indicate its manufacturing method, specifications, etc.
If an API manufacturer intends to sell an API to another company, the manufacturer will usually register an MF for the API.
Therefore, the number of officially registered MFs of a company is an indicator of the number of API products the company manufactures.
Year of Founding
1942
Daitoa Pharmaceutical Trade Control Company,* the predecessor of Daito, was founded as a control company in charge of the export of Toyama-made home medicines to Southeast Asia.
Daito will celebrate the 80th anniversary of its founding in June 2022.
- In 1991, the Company adopted its current name: Daito Pharmaceutical Co., Ltd.
Number of Employees (Consolidated)
1,073
（連結、2025年5月31日現在、臨時雇用者数を含む）
In the Daito Group, diverse talents demonstrate their capabilities fully, irrespective of their gender, nationality or age.
The Company has continued to grow since its listing on the Tokyo Stock Exchange, and it has employed many mid-career people.
Number of Staff Members of the Quality and Regulatory Affairs Division
220
(As of June 1, 2025, non-consolidated, including temporary employees)
Daito is committed to improving the quality of pharmaceuticals, and has 220 employees in its reliability assurance department, which includes the quality assurance department and quality control department.
This represents approximately 22% of Daito's total employee numbers (consolidated).
Number of Detailers
0
Since Daito concentrates its management resources on the manufacture of APIs and Pharmaceutical products, it outsources marketing activities targeting pharmacies and medical institutions to other companies.
Therefore, the Company has no detailers (MRs), who would be in charge of pharmaceutical detailing and sale to medical institutions.